Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Breast Cancer Heterogeneity and Response to Novel Therapeutics
Mariona Baliu‐Piqué, Atanasio Pandiella, Alberto Ocaña
Cancers (2020) Vol. 12, Iss. 11, pp. 3271-3271
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
Reyhaneh Farghadani, Rakesh Naidu
Cancers (2021) Vol. 13, Iss. 14, pp. 3427-3427
Open Access | Times Cited: 91
Circular RNAs: New layer of complexity evading breast cancer heterogeneity
Alyaa Dawoud, Z Zakaria, Hannah Hisham Rashwan, et al.
Non-coding RNA Research (2022) Vol. 8, Iss. 1, pp. 60-74
Open Access | Times Cited: 41
Phytocompounds-based therapeutic approach: Investigating curcumin and green tea extracts on MCF-7 breast cancer cell line
Radwa Fawzy, Amal AbdEl-Aziz, Khalid Bassiouny, et al.
Journal of Genetic Engineering and Biotechnology (2024) Vol. 22, Iss. 1, pp. 100339-100339
Open Access | Times Cited: 10
Competitive Endogenous Role of the LINC00511/miR-185-3p Axis and miR-301a-3p From Liquid Biopsy as Molecular Markers for Breast Cancer Diagnosis
Marwa M. Mahmoud, Eman F. Sanad, Reham A.A. Elshimy, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 50
A Systematic Review of PET Textural Analysis and Radiomics in Cancer
Manuel Piñeiro-Fiel, Alexis Moscoso, Virginia Pubul, et al.
Diagnostics (2021) Vol. 11, Iss. 2, pp. 380-380
Open Access | Times Cited: 47
Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications
Valérie Jacquemin, Mathieu Antoine, Geert Dom, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 280-280
Open Access | Times Cited: 35
Unlocking the power of precision medicine: exploring the role of biomarkers in cancer management
Dipak Gadade, Hariom Jha, Chetan Kumar, et al.
Future Journal of Pharmaceutical Sciences (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 8
Identification of autophagy‐related long non‐coding RNA prognostic signature for breast cancer
Qianxue Wu, Qing Li, Wenming Zhu, et al.
Journal of Cellular and Molecular Medicine (2021) Vol. 25, Iss. 8, pp. 4088-4098
Open Access | Times Cited: 33
The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways
Arshad Husain Rahmani, Ahmad Almatroudi, Amjad Ali Khan, et al.
Molecules (2022) Vol. 27, Iss. 22, pp. 8023-8023
Open Access | Times Cited: 26
Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer
Fatemeh Khojasteh Poor, Mona Keivan, Mohammad Ramazii, et al.
Breast Disease (2021) Vol. 40, Iss. 2, pp. 51-62
Closed Access | Times Cited: 28
Metabolic therapy and bioenergetic analysis: The missing piece of the puzzle
Tomás Duraj, Josefa Carrión-Navarro, Thomas N. Seyfried, et al.
Molecular Metabolism (2021) Vol. 54, pp. 101389-101389
Open Access | Times Cited: 28
Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC
Ha Rin Kim, Young Seok Cho, Seung Woo Chung, et al.
Journal of Controlled Release (2022) Vol. 346, pp. 136-147
Open Access | Times Cited: 20
Characteristics and prognostic significance of polo‐like kinase‐1 (PLK1) expression in breast cancer
Ayat G. Lashen, Michael S. Toss, Louisa M. Wootton, et al.
Histopathology (2023) Vol. 83, Iss. 3, pp. 414-425
Open Access | Times Cited: 12
Breast Cancer Heterogeneity and Its Implication in Precision Therapy
Fernando Candanedo-González, Ana Lilia Remírez-Castellanos, Ursula Salazar-Gomez, et al.
IntechOpen eBooks (2025)
Closed Access
Understanding metastasis mixed-treatment responses through genomic analyses
Susana García‐Recio, Paola Zagami, Brooke Felsheim, et al.
npj Breast Cancer (2025) Vol. 11, Iss. 1
Open Access
Advances in analytical approaches for background parenchymal enhancement in predicting breast tumor response to neoadjuvant chemotherapy: A systematic review
Thomas Julius, Lucas Malla, Benard Shibwabo
PLoS ONE (2025) Vol. 20, Iss. 3, pp. e0317240-e0317240
Open Access
Engineering a Vascularized 3D Hybrid System to Model Tumor-Stroma Interactions in Breast Cancer
Filipa Castro Teixeira, Sara Chaves, A.L. Torres, et al.
Frontiers in Bioengineering and Biotechnology (2021) Vol. 9
Open Access | Times Cited: 24
Synergic Role of Dietary Bioactive Compounds in Breast Cancer Chemoprevention and Combination Therapies
Marisabel Mecca, Marzia Sichetti, Martina Giuseffi, et al.
Nutrients (2024) Vol. 16, Iss. 12, pp. 1883-1883
Open Access | Times Cited: 3
Spatio-temporal modelling of phenotypic heterogeneity in tumour tissues and its impact on radiotherapy treatment
Giulia L. Celora, Helen M. Byrne, P. G. Kevrekidis
Journal of Theoretical Biology (2022) Vol. 556, pp. 111248-111248
Open Access | Times Cited: 16
LncRNA TDRKH-AS1 promotes breast cancer progression via the miR-134-5p/CREB1 axis
Yuqin Ding, Yu-Ting Huang, Fanrong Zhang, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 8
A Glycolysis-Based Long Non-coding RNA Signature Accurately Predicts Prognosis in Renal Carcinoma Patients
Honghao Cao, Hang Tong, Junlong Zhu, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 19
Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer
Young Seok Cho, Ha Rin Kim, Seong Jin Park, et al.
Biomaterials (2022) Vol. 289, pp. 121783-121783
Open Access | Times Cited: 13
The hallmarks of tissue-agnostic therapies and strategies for early anticancer drug discovery
Jihyeob Mun, Byungho Lim
Drug Discovery Today (2024) Vol. 29, Iss. 12, pp. 104203-104203
Open Access | Times Cited: 2
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
María del Mar Noblejas‐López, Lucía Gandullo‐Sánchez, Eva María Galán‐Moya, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5476-5476
Open Access | Times Cited: 11
Optimizing individualized treatment strategy based on breast cancer organoid model
Bo Pan, Xuelu Li, Dongyi Zhao, et al.
Clinical and Translational Medicine (2021) Vol. 11, Iss. 4
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top